Platelet-derived growth factor compositions and methods of use thereof

The present invention also provides a vial comprising platelet-derived growth factor (PDGF) at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid, when used in the preparation of the implant material of the invention.

A sixth aspect of the invention features an implant material that includes a porous calcium phosphate having adsorbed therein a liquid containing platelet-derived growth factor (PDGF) at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL. In several embodiments, the concentration of PDGF is about 0.3 mg/mL, the calcium phosphate is selected from tricalcium phosphate, hydroxyapatite, poorly crystalline hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, and octacalcium phosphate, and the PDGF is provided in a sterile liquid, for example, sodium acetate buffer.

A seventh aspect of the invention features a method of preparing an implant material by saturating a calcium phosphate material in a sterile liquid that includes platelet-derived growth factor (PDGF) at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL. In several embodiments, the concentration of PDGF is about 0.3 mg/mL, and the calcium phosphate is selected from tricalcium phosphate, hydroxyapatite, poorly crystalline hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, and octacalcium phosphate.

In an embodiment of all aspects of the invention, PDGF includes PDGF homoand heterodimers, for example, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD, and combinations and derivatives thereof.

The present invention also provides an implant material comprising a porous calcium phosphate having incorporated therein a liquid comprising platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL, wherein the calcium phosphate has a porosity greater than 40% and the calcium phosphate comprises particles in a range of about 100 microns to about 5000 microns in size.

The present invention also provides an implant material consisting of a porous calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein, the calcium phosphate has a porosity greater than 40% and the calcium phosphate consists of particles in a range of about 100 microns to about 5000 microns in size.

COMS ID No: ARCS-226281 Received by IP Australia: Time (H:m) 15:50 Date (Y-M-d) 2009-03-06

06/03 ’09 14:46 FAS 613 3618 4199 FB RICE & CO. @023

2005295919 06 Mar 2009

6A

Hie present invention also provides an implant material comprising a calcium phosphate having incorporated therein a liquid comprising platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL, wherein the implant material is a composition having a porosity that facilitates cellmigration into the composition and the calcium phosphate comprises particles in a range of about 100 microns to about 5000 microns in size.

The present invention also provides an implant material consisting of a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the implant material is a composition having a porosity that facilitates cell migration into the composition and the calcium phosphate consists of particles in a range of about 100 microns to about 5000 microns in size.

The present invention also provides an implant material comprising collagen and a porous calcium phosphate having incorporated therein a liquid comprising platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL, wherein the calcium phosphate has a porosity greater than 40% and the calcium phosphate comprises particles in a range of about 100 microns to about 5000 microns in size.

The present invention also provides an implant material consisting of collagen and a porous calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/triL in a buffer, wherein the calcium phosphate has a porosity greater than 40% and the calcium phosphate consists of particles in a range of about 100 microns to about 5000 microns in size,

The present invention also provides an implant material comprising collagen and a calcium phosphate having incorporated therein a liquid comprising platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL, wherein the implant material is a composition having a porosity that facilitates cell migration into the composition, and the calcium phosphate comprises particles in a range of about 100 microns to about 5000 microns in size.

The present invention also provides an implant material consisting of collagen and a calcium phosphate having incorporated therein a liquid consisting of platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer, wherein the implant material is a composition having a porosity that facilitates cell migration into the composition and the calcium phosphate consists of particles in a range of about 100 microns to about 5000 microns in size.

COMS ID No: ARCS-226281 Received by IP Australia: Time (H:m) 15:50 Date (Y-M-d) 2009-03-06

06/03 '09 14:47 FAX 613 8618 4199

KB RICE & CO.

@024

2005295919 06 Mar 2009

6B

The present invention also provides use of the implant material of the invention in the preparation of a medicament for promoting growth of bone, periodontium, ligament, or cartilage of a mammal.

The present invention also provides a method for promoting growth of bone, 5 periodontium, ligament, or cartilage of a mammal comprising administering to said mammal the implant materia) of the invention, wherein said implant material promotes the growth of said bone, periodontium, ligament, or cartilage.

In an embodiment of all aspects of the invention, the pharmaceutically acceptable carrier substance of the implant material is or additionally includes one or more of the following: a biocompatible binder (e.g., a natural or synthetic polymer), a

COMS ID No: ARCS-226281 Received by IP Australia: Time (H:m) 15:50 Date (Y-M-d) 2009-03-06

WO 2006/044334

PCT/US2005/036447 bone substituting agent, a liquid, and a gel. In another preferred embodiment, the implant material includes PDGF present in a pharmaceutically acceptable liquid carrier which is adsorbed by a pharmaceutically acceptable solid carrier.

In another embodiment of all aspects of the invention, the implant material is 5 prepared by combining isolated, partially purified, substantially purified, or purified

PDGF in an amount in the range of 0.1 to 1.0 mg/ml, more preferably 0.1 mg/ml, 0.3 mg/ml, or 1.0 mg/ml, most preferably 0.3 mg/ml, or even less than 0.1 mg/ml, with a pharmaceutically acceptable carrier substance, e.g., a biocompatible binder, such as a natural or synthetic polymer (e.g., collagen, polyglycolic acid, and polylactic acid), a bone substituting agent (e.g., a calcium phosphate (e.g., tricalcium phosphate or hydroxyapatite), calcium sulfate, or demineralized bone (e.g., demineralized freezedried cortical or cancellous bone), or a commercially available gel or liquid (i.e., a viscous or inert gel or liquid).

In several embodiments, the carrier substance of the implant material is, or additionally includes, one or more biocompatible binders. A biocompatible binder is an agent that produces or promotes cohesion between the combined substances. Nonlimiting examples of suitable biocompatible binders include polymers selected from polysaccharides, nucleic acids, carbohydrates, proteins, polypeptides, poly(a-hydroxy acids), poly(lactones), poly(amino acids), poly(anhydrides), poly(orthoesters), poly(anhydride-co-imides), poly(orthocarbonates), poly(a-hydroxy alkanoates), poly(dioxanones), poly(phosphoesters), polylactic acid, poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide (PLGA), poly(L-lactide-co-D, L-lactide), poly(D,L-lactide-co-trimethylene carbonate), polyglycolic acid, polyhydroxybutyrate (PHB), poly(e-caprolactone), poly(o25 valerolactone), poly(y-butyrolactone), poly(caprolactone), polyacrylic acid,

2006/044334

PCT/LS2005/036447 polycarboxylic acid, poly(allylamine hydrochloride), poly(diallyldimethylammonium chloride), poly(ethyleneimine), polypropylene fumarate, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene, polymethylmethacrylate, carbon fibers, polyethylene glycol), polyethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), polyethylene oxide)-co-poly(propylene oxide) block copolymers, polyethylene terephthalate)polyamide, and copolymers and mixtures thereof. Additional binders include alginic acid, arabic gum, guar gum, xantham gum, gelatin, chitin, chitosan, chitosan acetate, chitosan lactate, chondroitin sulfate, Ν,Ο-carboxymethyl chitosan, a dextran (e.g., «-cyclodextrin, /3-cyclodextrin, γ-cyclodextrin, or sodium dextran sulfate), fibrin glue, glycerol, hyaluronic acid, sodium hyaluronate, a cellulose (e.g., methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, or hydroxyethyl cellulose), a glucosamine, a proteoglycan, a starch (e.g., hydroxyethyl starch or starch soluble), lactic acid, a pluronic, sodium glycerophosphate, collagen, glycogen, a keratin, silk, and derivatives and mixtures thereof. In some embodiments, the biocompatible binder is t

water-soluble. A water-soluble binder dissolves from the implant material shortly after its implantation in vivo, thereby introducing macroporosity into the implant material. This macroporosity increases the osteoconductivity of the implant material by enhancing the access and, consequently, the remodeling activity of the osteoclasts and osteoblasts at the implant site.

The biocompatible binder may be added to the implant material in varying amounts and at a variety of stages during the preparation of the composition. Those of skill in the art will be able to determine the amount of binder and the method of inclusion required for a given application.

2006/044334

PCT/LS2005/036447

In an embodiment, the carrier substance is or includes a liquid selected from water, a buffer, and a cell culture medium. The liquid may be used in any pH range, but most often will be used in the range of pH 5.0 to pH 8.0. In an embodiment, the pH will be compatible with the prolonged stability and efficacy of the PDGF present in the implant material, or with the prolonged stability and efficacy of another desired biologically active agent. In most embodiments, the pH of the liquid will be in the range of pH 5.5 to pH 7.4. Suitable buffers include, but are not limited to, carbonates, phosphates (e.g., phosphate buffered saline), and organic buffers such as Tris,

HEPES, and MOPS. Most often, the buffer will be selected for its biocompatibility with the host tissues and its compatibility with the biologically active agent. For most applications in which nucleic acids, peptides, or antibiotics are included in the implant material, a simple phosphate buffered saline will suffice.

In another embodiment of all aspects of the invention, the carrier substance of the implant material is, or additionally includes, one or more bone substituting agents. A bone substituting agent is one that can be used to permanently or temporarily replace bone. Following implantation, the bone substituting agent can be retained by the body or it can be resorbed by the body and replaced with bone. Exemplary bone substituting agent include, e.g., a calcium phosphate (e.g., tricalcium phosphate (e.g., (3-TCP), hydroxyapatite, poorly crystalline hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, and octacalcium phosphate), calcium sulfate, or demineralized bone (e.g., demineralized freeze-dried cortical or cancellous bone)). In an embodiment, the carrier substance is bioresorbable. In another embodiment, the bone substituting agent is provided as a matrix of micron- or submicron- sized particles, e.g., nano-sized particles. The

2005295919 04 Feb 2008 ίο particles can be in the range of about 100 pm to about 5000 pm in size, more preferably in the range of about 100 pm to about 3000 pm, more preferably in the range of about 200 pm to about 3000 pm, and most preferably in the range of about 250 pm to about 2000 pm, or about 250 pm to about 1000 pm, or the particles can be in the range of about 1 nm to about 1000 nm, preferably less than about 500 nm, and more preferably less than about 250 nm. In another embodiment, the bone substituting agent has a porous composition. Porosity of the composition is a desirable characteristic as it facilitates cell migration and infiltration into the composition so that the cells can secrete extracellular bone matrix. It also provides access for vascularization. Porosity also provides a high surface area for enhanced resorption and release of active substances, as well as increased cell-matrix interaction. Preferably, the composition has a porosity of greater than 40%, more preferably greater than 65%, and most preferably greater than 90%. The composition can be provided in a shape suitable for implantation (e.g., a sphere, a cylinder, or a block) or it can be sized and shaped prior to use. In a preferred embodiment, the bone substituting agent is a calcium phosphate (e.g., β-TCP).

The bone substituting agent can also be provided as a flowable, moldable paste or putty. Preferably, the bone substituting agent is a calcium phosphate paste that selfhardens to form a hardened calcium phosphate prior to or after implantation in vivo.

The calcium phosphate component of the invention may be any biocompatible calcium phosphate material known in the art. The calcium phosphate material may be produced by any one of a variety of methods and using any suitable starting components. For example, the calcium phosphate material may include amorphous, apatitic calcium phosphate. Calcium phosphate material may be produced by solid-state acid-base reaction of crystalline calcium phosphate reactants

2006/044334

PCT/LS2005/036447 to form crystalline hydroxyapatite solids. Other methods of making calcium phosphate materials are known in the art, some of which are described below.

The calcium phosphate material can be poorly crystalline apatitic (PCA) calcium phosphate or hydroxyapatite (HA). PCA material is described in application U.S. Patent Nos. 5,650,176; 5,783,217; 6,027,742; 6,214,368; 6,287,341; 6,331,312; and 6,541,037, all of which are incorporated herein by reference. HA is described, for example, in U.S. Patent Nos. Re. 33,221 and Re. 33,161. These patents teach preparation of calcium phosphate remineralization compositions and of a finely crystalline, non-ceramic, gradually resorbable hydroxyapatite carrier material based on the same calcium phosphate composition. A similar calcium phosphate system, which consists of tetracalcium phosphate (TTCP) and monocalcium phosphate (MCP) or its monohydrate form (MCPM), is described in U.S. Patent Nos. 5,053,212 and 5,129,905. This calcium phosphate material is produced by solid-state acid-base reaction of crystalline calcium phosphate reactants to form crystalline hydroxyapatite solids.

Crystalline HA materials (commonly referred to as dahllite) maybe prepared such that they are flowable, moldable, and capable of hardening in situ (see U.S.

Patent No. 5,962,028). These HA materials (commonly referred to as carbonated hydroxyapatite) can be fonned by combining the reactants with a non-aqueous liquid to provide a substantially uniform mixture, shaping the mixture as appropriate, and allowing the mixture to harden in the presence of water (e.g., before or after implantation). During hardening, the mixture crystallizes into a solid and essentially monolithic apatitic structure.

WO 2006/044334

PCT/LS2005/036447

The reactants will generally consist of a phosphate source, e.g., phosphoric acid or phosphate salts, substantially free of water, an alkali earth metal, particularly calcium, source, optionally crystalline nuclei, particularly hydroxyapatite or calcium

I phosphate crystals, calcium carbonate, and a physiologically acceptable lubricant, such as any of the non-aqueous liquids described herein. The dry ingredients may be pre-prepared as a mixture and subsequently combined with the non-aqueous liquid ingredients under conditions where substantially uniform mixing occurs.

The calcium phosphate material is characterized by its biological resorbability, biocompatibility, and its minimal crystallinity. Its crystalline character is substantially the same as natural bone. Preferably, the calcium phosphate material hardens in less than five hours, and substantially hardens in about one to five hours, under physiological conditions. Preferably, the material is substantially hardened within about 10-30 minutes. The hardening rate under physiological conditions, may be varied according to the therapeutic need by modifying a few simple parameters as described in U.S. Patent No. 6,027,742, which is incorporated herein by reference.

In an embodiment, the resulting bioresorbable calcium phosphate material will be “calcium deficient,” with a calcium to phosphate molar ratio of less than about 1.6 , as compared to the ideal stoichiometric value of approximately 1.67 for hydroxyapatite.

Desirable calcium phosphates are capable of hardening in a moist environment, at or around body temperature in less than 5 hours and preferably within 10-30 minutes. Desirable materials are those that, when implanted as a 1-5 g pellet, are at least 80% resorbed within one year. Preferably, the material can be fully resorbed.

2006/044334

PCT/LS2005/036447

In several embodiments of all aspects of the invention, the implant material additionally may include one or more biologically active agents. Biologically active agents that can be incorporated into the implant materials of the invention include, without limitation, organic molecules, inorganic materials, proteins, peptides, nucleic acids (e.g., genes, gene fragments, gene regulatory sequences, and antisense molecules), nucleoproteins, polysaccharides, glycoproteins, and lipoproteins. Classes of biologically active compounds that can be incorporated into the implant materials of the invention include, without limitation, anti-cancer agents, antibiotics, analgesics, anti-inflammatory agents, immunosuppressants, enzyme inhibitors, antihistamines, anti-convulsants, hormones, muscle relaxants, anti-spasmodics, ophthalmic agents, prostaglandins, anti-depressants, anti-psychotic substances, trophic factors, osteoinductive proteins, growth factors, and vaccines.

Anti-cancer agents include alkylating agents, platinum agents, antimetabolites, topoisomerase inhibitors, antitumor antibiotics, antimitotic agents, aromatase inhibitors, thymidylate synthase inhibitors, DNA antagonists, famesyltransferase inhibitors, pump inhibitors, histone acetyltransferase inhibitors, metalloproteinase inhibitors, ribonucleoside reductase inhibitors, TNF alpha agonists/antagonists, endothelin A receptor antagonists, retinoic acid receptor agonists, immunomodulators, hormonal and antihormonal agents, photodynamic agents, and tyrosine kinase inhibitors.

WO 2006/044334

PCT/LS2005/036447

Any of the biologically active agents listed in Table 1 can be used.

Table 1.

<td> Alkylating agents</td><td> cyclophosphamide busulfan ifosfamide melphalan hexamethylmelamine thiotepa chlorambucil dacarbazine carmustine</td><td> lomustine procarbazine altretamine estramustine phosphate mechlorethamine streptozocin temozolomide semustine</td>

<td></td><td></td><td></td>

<td> Platinum agents</td><td> cisplatin oxaliplatin spiroplatinum, carboxyphthalatoplatinum, tetraplatin ormiplatin iproplatin</td><td> carboplatinum ZD-0473 (AnorMED) lobaplatin (Aetema) satraplatin (Johnson Matthey) BBR-3464 (Hoffmann-La Roche) SM-11355 (Sumitomo) AP-5280 (Access)</td>

<td></td><td></td><td></td>

<td> Antimetabolites</td><td> azacytidine gemcitabine capecitabine 5- fluorouracil floxuridine 2-chlorodeoxyadenosine 6- mercaptopurine 6-thioguanine cytarabin 2-fluorodeoxy cytidine methotrexate idatrexate</td><td> tomudex trimetrexate deoxycoformycin fludarabine pentostatin raltitrexed hydroxyurea decitabine (SuperGen) clofarabine (Bioenvision) irofulven (MGI Pharma) DMDC (Hoffmann-La Roche) ethynylcytidine (Taiho)</td>

<td></td><td></td><td></td>

<td> Topoisomerase inhibitors</td><td> amsacrine epirubicin etoposide teniposide or mitoxantrone irinotecan (CPT-11) 7-ethyl-10-hydroxy-camptothecin topotecan dexrazoxanet (TopoTarget) pixantrone (Novuspharma) rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharma)</td><td> rubitecan (SuperGen) exatecan mesylate (Daiichi) quinamed (ChemGenex) gimatecan (Sigma-Tau) diflomotecan (Beaufour-Ipsen) TAS-103 (Taiho) elsamitrucin (Spectrum) J-107088 (Merck &amp; Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun Dang) KW-2170 (Kyowa Hakko)</td>

<td></td><td></td><td></td>

WO 2006/044334

PCT/US2005/036447

<td> Antitumor antibiotics</td><td> dactinomycin (actinomycin D) doxorubicin (adriamycin) deoxyrubicin valrubicin daunorubicin (daunomycin) epirubicin therarubicin idarubicin rubidazone plicamycinp porfbomycin cyanomorpholinodoxorubicin mitoxantrone (novantrone)</td><td> amonaflde azonafide anthrapyrazole oxantrazole losoxantrone bleomycin sulfate (blenoxane) bleomycinic acid bleomycin A bleomycin B mitomycin C MEN-10755 (Menarini) GPX-100 (Gem Pharmaceuticals)</td>

<td></td><td></td><td> I</td>

<td> Antimitotic agents</td><td> paclitaxel docetaxel colchicine vinblastine vincristine vinorelbine vindesine dolastatin 10 (NCI) rhizoxin (Fujisawa) mivobulin (Warner-Lambert) cemadotin (BASF) RPR 109881A (Aventis) TXD 258 (Aventis) epothilone B (Novartis) T 900607 (Tularik) T 138067 (Tularik) cryptophycin 52 (Eli Lilly) vinflunine (Fabre) auristatin PE (Teikoku Hormone) BMS 247550 (BMS) BMS 184476 (BMS) BMS 188797 (BMS) taxoprexin (Protarga)</td><td> SB 408075 (GlaxoSmithKline) E7010 (Abbott) PG-TXL (Cell Therapeutics) IDN 5109 (Bayer) A 105972 (Abbott) A 204197 (Abbott) LU 223651 (BASF) D 24851 (ASTAMedica) ER-86526 (Eisai) combretastatin A4 (BMS) isohomohalichondrin-B (PharmaMar) ZD 6126 (AstraZeneca) PEG-paclitaxel (Enzon) AZ10992 (Asahi) IDN-5109 (Indena) AVLB (Prescient NeuroPharma) azaepothilone B (BMS) BNP-7787 (BioNumerik) CA-4 prodrug (OXiGENE) dolastatin-10 (NIH) CA-4 (OXiGENE)</td>

<td></td><td></td><td></td>

<td> Aromatase inhibitors</td><td> aminoglutethimide letrozole anastrazole formes tane</td><td> exemestane atamestane (BioMedicines) YM-511 (Yamanouchi)</td>

<td></td><td></td><td></td>

<td> Thymidylate synthase inhibitors</td><td> pemetrexed (Eli Lilly) ZD-9331 (BTG)</td><td> nolatrexed (Eximias) CoFactor™ (BioKeys)</td>

<td></td><td></td><td></td>

<td> DNA antagonists</td><td> trabectedin (PharmaMar) glufosfamide (Baxter International) albumin + 32P (Isotope Solutions) thymectacin (NewBiotics) edotreotide (Novartis)</td><td> mafosfamide (Baxter International) apaziquone (Spectrum Pharmaceuticals) 06 benzyl guanine (Paligent)</td>

<td></td><td></td><td></td>

<td> Famesyltransferase inhibitors</td><td> arglabin (NuOncology Labs) lonafamib (Schering-Plough) BAY-43-9006 (Bayer)</td><td> tipifamib (Johnson &amp; Johnson) perillyl alcohol (DOR BioPharma)</td>

<td></td><td></td><td></td>

<td> Pump inhibitors</td><td> CBT-1 (CBA Pharma) tariquidar (Xenova) MS-209 (ScheringAG)</td><td> zosuquidar trihydrochloride (Eli Lilly) biricodar dicitrate (Vertex)</td>

WO 2006/044334

PCT/US2005/036447

<td></td><td></td><td></td>

<td> Histone acetyltransferase ¹ inhibitors</td><td> tacedinahne (Pfizer) SAHA (Aton Pharma) MS-275 (ScheringAG)</td><td> pivaloyloxymethyl butyrate (Titan) depsipeptide (Fujisawa)</td>

<td></td><td></td><td></td>

<td> Metalloproteinase inhibitors</td><td> Neovastat (Aetema Laboratories) marimastat (British Biotech)</td><td> CMT-3 (CollaGenex) BMS-275291 (Celltech)</td>

<td></td><td></td><td></td>

<td> Ribonucleoside reductase inhibitors</td><td> gallium maltolate (Titan) triapine (Vion)</td><td> tezacitabine (Aventis) didox (Molecules for Health)</td>

<td></td><td></td><td></td>

<td> TNT alpha agonists/antagonists</td><td> virulizin (Lorus Therapeutics) CDC-394 (Celgene) infliximab (Centocor, Inc.) adalimumab (Abbott Laboratories)</td><td> revimid (Celgene) entanercept (Immunex Corp.)</td>

<td></td><td></td><td></td>

<td> Endothelin A receptor antagonist</td><td> atrasentan (Abbott) ZD-4054 (AstraZeneca)</td><td> YM-598 (Yamanouchi)</td>

<td></td><td></td><td></td>

<td> Retinoic acid receptor agonists</td><td> fenretinide (Johnson &amp; Johnson) LGD-1550 (Ligand)</td><td> alitretinoin (Ligand)</td>

<td></td><td></td><td></td>

<td> Immuno- modulators</td><td> interferon oncophage (Antigenics) GMK (Progenies) adenocarcinoma vaccine (Biomira) CTP-37 (AVI BioPharma) IRX-2 (Immuno-Rx) PEP-005 (Peplin Biotech) synchrovax vaccines (CTL Immuno) melanoma vaccine (CTL Immuno) p21 RAS vaccine (GemVax)</td><td> dexosome therapy (Anosys) pentrix (Australian Cancer Technology) ISF-154 (Tragen) cancer vaccine (Intercell) norelin (Biostar) BLP-25 (Biomira) MGV (Progenies) β-alethine (Dovetail) CLL therapy (Vasogen)</td>

<td></td><td></td><td></td>

<td> Hormonal and antihormonal agents 1</td><td> estrogens conjugated estrogens ethinyl estradiol chlortrianisen idenestrol hydroxyprogesterone caproate medroxyprogesterone testosterone testosterone propionate; fluoxymesterone methyltestosterone diethylstilbestrol megestrol tamoxifen toremofine dexamethasone</td><td> prednisone methylprednisolone prednisolone aminoglutethimide leuprolide goserelin leuporelin bicalutamide flutamide octreotide nilutamide mitotane P-04 (Novogen) 2-methoxyestradiol (EntreMed) arzoxifene (Eli Lilly)</td>

<td></td><td></td><td></td>

<td> Photodynamic agents</td><td> talaporfin (Light Sciences) Theralux (Theratechnologies) motexafin gadolinium (Pharmacyclics)</td><td> Pd-bacteriopheophorbide (Yeda) lutetium texaphyrin (Pharmacyclics) hypericin</td>

<td></td><td></td><td></td>

WO 2006/044334

PCT/LS2005/036447

<td> Tyrosine Kinase Inhibitors</td><td> imatinih (Novartis) leflunomide (Sugen/Pharmacia) ZD1839 (AstraZeneca) erlotinib (Oncogene Science) canertinib (Pfizer) squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia ) ZD4190 (AstraZeneca) ZD6474 (AstraZeneca) vatalanib (Novartis) PKI166 (Novartis) GW2016 (GlaxoSmithKline) EKB-509 (Wyeth) EKB-569 (Wyeth)</td><td> kahalide F (PharmaMar) CEP-701 (Cephalon) CEP-751 (Cephalon) MLN5I8 (Millenium) PKC412 (Novartis) phenoxodiol () trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech) MDX-H210 (Medarex) 2C4 (Genentech) MDX-447 (Medarex) ABX-EGF (Abgenix) IMC-1C11 (ImClone)</td>

<td></td><td></td><td></td>

Antibiotics include aminoglycosides (e.g., gentamicin, tobramycin, netilmicin, streptomycin, amikacin, neomycin), bacitracin, corbapenems (e.g., imipenem/cislastatin), cephalosporins, colistin, methenamine, monobactams (e.g., aztreonam), penicillins (e.g., penicillin G, penicillin V, methicillin, natcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, mezlocillin, azlocillin), polymyxin B, quinolones, and vancomycin; and bacteriostatic agents such as chloramphenicol, clindanyan, macrolides (e.g., erythromycin, azithromycin, clarithromycin), lincomyan, nitrofurantoin, sulfonamides, tetracyclines (e.g., tetracycline, doxycycline, minocycline, demeclocyline), and trimethoprim. Also included are metronidazole, fluoroquinolones, and rifampin.

Enzyme inhibitors are substances which inhibit an enzymatic reaction. Examples of enzyme inhibitors include edrophonium chloride, Nmethylphysostigmine, neostigmine bromide, physostigmine sulfate, tacrine, tacrine, 115 hydroxy maleate, iodotubercidin, p-bromotetramisole, 10-(alphadiethylaminopropionyl)-phenothiazine hydrochloride, calmidazolium chloride, hemicholinium-3, 3,5-dinitrocatechol, diacylglycerol kinase inhibitor I, diacylglycerol kinase inhibitor II, 3-phenylpropargylamine, N⁶-monomethyl-L-arginine acetate,

2006/044334

PCT/US2005/036447 carbidopa, 3-hydroxybenzylhydrazine, hydralazine, clorgyline, deprenyl, hydroxylamine, iproniazid phosphate, 6-MeO-tetrahydro-9H-pyrido-indole, nialamide, pargyline, quinacrine, semicarbazide, tranylcypromine, N,Ndiethylaminoethyl-2,2-diphenylvalerate hydrochloride, 3-isobutyl-1 -methylxanthne, papaverine, indomethacind, 2-cyclooctyl-2-hydroxyethylamine hydrochloride, 2,3dichloro-a-methylbenzylamine (DCMB), 8,9-dichloro-2,3,4,5-tetrahydro-l H-2benzazepine hydrochloride, p-aminoglutethimide, p-aminoglutethimide tartrate, 3iodotyrosine, alpha-methyltyrosine, acetazolamide, dichlorphenamide, 6-hydroxy-2benzothiazolesulfonamide, and allopurinol.

Antihistamines include pyrilamine, chlorpheniramine, and tetrahydrazoline, among others.

Anti-inflammatory agents include corticosteroids, nonsteroidal antiinflammatory drugs (e.g., aspirin, phenylbutazone, indomethacin, sulindac, tolmetin, ibuprofen, piroxicam, and fenamates), acetaminophen, phenacetin, gold salts, chloroquine, D-Penicillamine, methotrexate colchicine, allopurinol, probenecid, and sulfinpyrazone.

Muscle relaxants include mephenesin, methocarbomal, cyclobenzaprine hydrochloride, trihexylphenidyl hydrochloride, levodopa/carbidopa, and biperiden.

Anti-spasmodics include atropine, scopolamine, oxyphenonium, and papaverine. ,

Analgesics include aspirin, phenybutazone, idomethacin, sulindac, tolmetic, ibuprofen, piroxicam, fenamates, acetaminophen, phenacetin, morphine sulfate, codeine sulfate, meperidine, nalorphine, opioids (e.g., codeine sulfate, fentanyl citrate, hydrocodone bitartrate, loperamide, morphine sulfate, noscapine, norcodeine,

2006/044334

PCT/LS2005/036447 normorphine, thebaine, nor-binaltorphimine, buprenorphine, chlomaltrexamine, funaltrexamione, nalbuphine, nalorphine, naloxone, naloxonazine, naltrexone, and naltrindole), procaine, lidocain, tetracaine and dibucaine.

Ophthalmic agents include sodium fluorescein, rose bengal, methacholine, adrenaline, cocaine, atropine, alpha-chymotrypsin, hyaluronidase, betaxalol, pilocarpine, timolol, timolol salts, and combinations thereof.

Prostaglandins are art recognized and are a class of naturally occurring chemically related, long-chain hydroxy fatty acids that have a variety of biological effects.

Anti-depressants are substances capable of preventing or relieving depression. Examples of anti-depressants include imipramine, amitriptyline, nortriptyline, protriptyline, desipramine, amoxapine, doxepin, maprotiline, tranylcypromine, phenelzine, and isocarboxazide.

Growth factors are factors whose continued presence improves the viability or longevity of a cell. Trophic factors include, without limitation, neutrophil-activating protein, monocyte chemoattractant protein, macrophage-inflammatory protein, platelet factor, platelet basic protein, and melanoma growth stimulating activity; epidermal growth factor, transforming growth factor (alpha), fibroblast growth factor, platelet-derived endothelial cell growth factor, insulin-like growth factor (IGF, e.g., IGF-I or IGF-Π), glial derived growth neurotrophic factor, ciliary neurotrophic factor, nerve growth factor, bone growth/cartilage-inducing factor (alpha and beta), bone morphogenetic proteins (BMPs), interleukins (e.g., interleukin inhibitors or interleukin receptors, including interleukin 1 through interleukin 10), interferons (e.g., interferon alpha, beta and gamma), hematopoietic factors, including erythropoietin, granulocyte colony stimulating factor, macrophage colony stimulating factor and

2006/044334

PCT/US2005/036447 granulocyte-macrophage colony stimulating factor; tumor necrosis factors, transforming growth factors (beta), including beta-1, beta-2, beta-3, transforming growth factors (alpha), inhibin, and activin; and bone morphogenetic proteins such as OP-1, BMP-2 and BMP-7.

Hormones include estrogens (e.g., estradiol, estrone, estriol, diethylstibestrol, quinestrol, chlorotrianisene, ethinyl estradiol, mestranol), anti-estrogens (e.g., clomiphene, tamoxifen), progestins (e.g., medroxyprogesterone, norethindrone, hydroxyprogesterone, norgestrel), antiprogestin (mifepristone), androgens (e.g, testosterone cypionate, fluoxymesterone, danazol, testolactone), anti-androgens (e.g., cyproterone acetate, flutamide), thyroid hormones (e.g., triiodothyronne, thyroxine, propylthiouracil, methimazole, and iodixode), and pituitary hormones (e.g., corticotropin, sumutotropin, oxytocin, and vasopressin). Hormones are commonly employed in hormone replacement therapy and/or for purposes of birth control. Steroid hormones, such as prednisone, are also used as immunosuppressants and antiinflammatories.

The biologically active agent is also desirably selected from the family of proteins known as the transforming growth factors-beta (TGF-/3) superfamily of proteins, which includes the activins, inhibins, and bone morphogenetic proteins (BMPs), hr an embodiment, the active agent includes at least one protein selected from the subclass of proteins known generally as BMPs, which have been disclosed to have osteogenic activity, and other growth and differentiation type activities. These BMPs include BMP proteins BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7, disclosed for instance in U.S. Patent Nos. 5,108,922; 5,013,649; 5,116,738;

5,106,748; 5,187,076; and 5,141,905; BMP-8, disclosed in PCT publication WO91/18098; and BMP-9, disclosed in PCT publication W093/00432, BMP-10,

2006/044334

PCT/LS2005/036447 disclosed in PCT application WO94/26893; BMP-11, disclosed in PCT application WO94/26892, or BMP-12 or BMP-13, disclosed in PCT application WO 95/16035; BMP-14; BMP-15, disclosed in U.S. Patent No. 5,635,372; or BMP-16, disclosed in U.S. Patent No. 5,965,403. Other TGF-/3 proteins which may be useful as the active agent in the calcium phosphate compositions of the invention include Vgr-2, Jones et al., Mol. Endocrinol. 6:1961 (1992), and any of the growth and differentiation factors (GDFs), including those described in PCT applications WO94/15965; WO94/15949; W095/01801; W095/01802; WO94/21681; WO94/15966; WO95/10539; WO96/01845; WO96/02559 and others. Also useful in the invention may be BIP, disclosed in WO94/01557; HP00269, disclosed in JP Publication number: 7-250688; and MP52, disclosed in PCT application WO93/16099. The disclosures of all of the above applications are incorporated herein by reference. A subset of BMPs which can be used in the invention include BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-10,

BMP-12, BMP-13, BMP-14, and MP52. The active agent is most preferably BMP-2, the sequence of which is disclosed in U.S. Patent No. 5,013,649, the disclosure of which is incorporated herein by reference. Other osteogenic agents known in the art can also be used, such as teriparatide (Forteo™), Chrysalin®, prostaglandin E2, LIM protein, osteogenin, or demineralized bone matrix (DBM), among others.

The biologically active agent may be synthesized chemically, recombinantly produced, or purified from a source in which the biologically active agent is naturally found. The active agent, if a TGF-/3, such as a BMP or other dimeric protein, may be homodimeric, or may be heterodimeric with other BMPs (e.g., a heterodimer composed of one monomer each of BMP-2 and BMP-6) or with other members of the TGF-/3 superfamily, such as activins, inhibins and TGF-/31 (e.g., a heterodimer composed of one monomer each of a BMP and a related member of the TGF-/3

WO 2006/044334

PCT/US2005/036447 superfamily). Examples of such heterodimeric proteins are described for example in Published PCT Patent Application WO 93/09229, the specification of which is incorporated herein by reference.

Additional biologically active agents include the Hedgehog, Frazzled,

Chordin, Noggin, Cerberus, and Follistatin proteins. These families of proteins are generally described in Sasai et al., Cell 79:779-790 (1994) (Chordin); PCT Patent Publication W094/05800 (Noggin); and Fukui et al., Devel. Biol. 159:131 (1993) (Follistatin). Hedgehog proteins are described in WO96/16668; WO96/17924; and WO95/18856. The Frazzled family of proteins is a recently discovered family of proteins with high homology to the extracellular binding domain of the receptor protein family known as Frizzled. The Frizzled family of genes and proteins is described in Wang et al., J. Biol. Chem. 271:4468-4476 (1996). The active agent may also include other soluble receptors, such as the truncated soluble receptors disclosed in PCT patent publication WO95/07982. From the teaching of WO95/07982, one skilled in the art will recognize that truncated soluble receptors can be prepared for numerous other receptor proteins. The above publications are incorporated by reference herein.

The amount of the biologically active protein, e.g., an osteogenic protein, that is effective to stimulate a desired activity, e.g., increased osteogenic activity of present or infiltrating progenitor or other cells, will depend upon the size and nature of the defect being treated, as well as the carrier being employed. Generally, the amount of protein to be delivered is in a range of from about 0.1 to about 100 mg; preferably about 1 to about 100 mg; most preferably about 10 to about 80 mg.

WO 2006/044334

PCT/LS2005/036447

Standard protocols and regimens for delivery of the above-listed agents are known in the art. Biologically active agents are introduced into the implant material in amounts that allow delivery of an appropriate dosage of the agent to the implant site. In most cases, dosages are determined using guidelines known to practitioners and applicable to the particular agent in question. The exemplary amount of biologically active agent to be included in the implant material of the invention is likely to depend on such variables as the type and extent of the condition, the overall health status of the particular patient, the formulation of the active agent, and the bioresorbability of the delivery vehicle used. Standard clinical trials may be used to optimize the dose and dosing frequency for any particular biologically active agent.

In an embodiment of all aspects of the invention, the composition can additionally contain autologous bone marrow or autologous platelet extracts.

( ' In another embodiment of all of the above aspects, the PDGF and/or other growth factors can be obtained from natural sources, (e.g., platelets), or more preferably, produced by recombinant DNA technology. When obtained from natural sources, the PDGF and/or other growth factors can be obtained from a biological fluid. A biological fluid includes any treated or untreated fluid (including a suspension) associated with living organisms, particularly blood, including whole blood, warm or cold blood, and stored or fresh blood; treated blood, such as blood diluted with at least one physiological solution, including but not limited to saline, nutrient, and/or anticoagulant solutions; blood components, such as platelet concentrate (PC), apheresed platelets, platelet-rich plasma (PRP), platelet-poor plasma (PPP), platelet-free plasma, plasma, serum, fresh frozen plasma (FFP), components obtained from plasma, packed red cells (PRC), buffy coat (BC); blood products derived from blood or a blood component or derived from bone marrow; red

2006/044334

PCT/US2005/036447 cells separated from plasma and resuspended in physiological fluid; and platelets separated from plasma and resuspended in physiological fluid. The biological fluid may have been treated to remove some of the leukocytes before being processed according to the invention. As used herein, blood product or biological fluid refers to the components described above, and to similar blood products or biological fluids obtained by other means and with similar properties. In an embodiment, the PDGF is obtained from platelet-rich plasma (PRP). The preparation of PRP is described in, e.g., U.S. Patent Nos. 6,649,072, 6,641,552, 6,613,566, 6,592,507, 6,558,307, 6,398,972, and 5,599,558, which are incorporated herein by reference.

In an embodiment of all aspects of the invention, the implant material delivers PDGF at the implant site for a duration of time greater than at least 1 day. In several embodiments, the implant material delivers PDGF at the implant site for at least 7,14, 21, or 28 days. Preferably, the implant material delivers PDGF at the implant site for a time between about 1 day and 7, 14, 21, or 28 days. In another embodiment, the implant material delivers PDGF at the implant site for a time greater than about 1 day, but less than about 14 days.

By “bioresorbable” is meant the ability of the implant material to be resorbed or remodeled in vivo. The resorption process involves degradation and elimination of the original implant material through the action of body fluids, enzymes or cells. The resorbed materials may be used by the host in the formation of new tissue, or it may be otherwise re-utilized by the host, or it may be excreted.

By “differentiation factor” is meant a polypeptide, including a chain of at least amino acids, which stimulates differentiation of one or more target cells into cells with cartilage or bone forming potential.

WO 2006/044334

PCT/US2005/036447

By “nanometer-sized particle” is meant a submicron-sized particle, generally defined as a particle below 1000 nanometers. A nanometer-sized particle is a solid particle material that is in an intermediate state between molecular and macron substances. A nanometer is defined as one billionth of a meter (1 nanometer = 10⁹

m). Nanometer material is known as the powder, fiber, film, or block having nanoscale size.

By “periodontium” is meant the tissues that surround and support the teeth.

The periodontium supports, protects, and provides nourishment to the teeth. The periodontium consists of bone, cementum, alveolar process of the maxillae and mandible, periodontal ligament, and gingiva. Cementum is a thin, calcified layer of tissue that completely covers the dentin of the tooth root. Cementum is formed during the development of the root and throughout the life of the tooth and functions as an area of attachment for the periodontal ligament fibers. The alveolar process is the bony portion of the maxilla and mandible where the teeth are embedded and in which the tooth roots are supported. The alveolar socket is the cavity within the alveolar process in which the root of the tooth is held by the periodontal ligament. The bone that divides one socket from another is called the interdental septum. When multirooted teeth are present, the bone is called the interradicular septum.

The alveolar process includes the cortical plate, alveolar crest, trabecular bone, and the alveolar bone proper.

By “promoting growth” is meant the healing of bone, periodontium, ligament, or cartilage, and regeneration of such tissues and structures. Preferably, the bone, periodontium, ligament, or cartilage is damaged or wounded and requires regeneration or healing.

WO 2006/044334

PCT/US2005/036447

By “promoting periodontium growth” is meant regeneration or healing of the supporting tissues of a tooth including alveolar bone, cementum, and interposed periodontal ligament, which have been damaged by disease or trauma.

By “purified” is meant a growth or differentiation factor, e.g., PDGF, which, prior to mixing with a carrier substance, is 95% or greater by weight, i.e., the factor is substantially free of other proteins, lipids, and carbohydrates with which it is naturally associated. The term “substantially purified” refers to a lesser purity of factor, having, for example, only 5%-95% by weight of the factor, preferably 65-95%. A purified protein preparation will generally yield a single major band on a polyacrylamide gel. Most preferably, the purified factor used in implant materials of the invention is pure as judged by amino-terminal amino acid sequence analysis. The term “partially purified” refers to PDGF that is provided in the context of PRP, PPP, FFP, or any other blood product that requires collection and separation, e.g., by centrifugation, to produce.

By way of example, a solution having ~1.0 mg/mL of PDGF, when ~50% pure, constitutes ~2.0 mg/niL of total protein.

The implant materials of this invention aid in regeneration of periodontium, at least in part, by promoting the growth of connective tissue, bone, and cementum. The implant materials can be prepared so that they directly promote the growth and differentiation of cells that produce connective tissue, bone, and cementum.

Alternatively, the implant materials can be prepared so that they act indirectly by, e.g., attracting cells that are necessary for promoting the growth of connective tissue, bone, and cementum. Regeneration using a composition of this invention is a more effective treatment of periodontal diseases or bone wounds than that achieved using systemic antibiotics or surgical debridement alone.

WO 2006/044334

PCT/LS2005/036447

The PDGF, polypeptide growth factors, and differentiation factors may be obtained from human tissues or cells, e.g., platelets, by solid phase peptide synthesis, or by recombinant DNA technology. Thus, by the term “polypeptide growth factor” or “differentiation factor,” we mean tissue or cell-derived, recombinant, or synthesized materials. If the factor is a dimer, e.g., PDGF, the recombinant factor can be a recombinant heterodimer, made by inserting into cultured prokaryotic or eukaryotic cells DNA sequences encoding both subunits of the factor, and then allowing the translated subunits to be processed by the cells to form a heterodimer (e.g., PDGF-AB). Alternatively, DNA encoding just one of the subunits (e.g., PDGF

B-chain or A-chain) can be inserted into cells, which then are cultured to produce the homodimeric factor (e.g., PDGF-BB or PDGF-AA homodimers). PDGF for use in the methods of the invention includes PDGF homo- and heterodimers, for example,

PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD, and combinations and derivatives thereof.

The concentration of PDGF or other growth factors of the invention can be determined by using, e.g., an enzyme-linked immunoassay, as described in, e.g., U.S. Patent Nos. 6,221,625, 5,747,273, and 5,290,708, incorporated herein by reference, or any other assay known in the art for determining protein concentration. When provided herein, the molar concentration of PDGF is determined based on the molecular weight of PDGF dimer (e.g., PDGF-BB; MW= approximately 25 kDa).

The methods and implant materials of the invention can be used to heal bony wounds of mammals, e.g., fractures, implant recipient sites, and sites of periodontal disease. The implant materials promote connective tissue growth and repair and enhance bone formation compared to natural healing (i.e., no exogenous agents added) or healing supplemented by addition of systemic antibiotics. Unlike natural

2005295919 17 May 2007 healing, conventional surgical therapy, or antibiotics, the implant materials of the invention prompt increased bone, connective tissue (e.g., cartilage and ligament), and cementum formation when applied to damaged or diseased tissues or to periodontal disease affected sites. The restoration of these tissues leads to an improved prognosis for the affected areas. The ability of these factors to stimulate new bone formation also makes it applicable for treating bony defects caused by other types of infection or surgical or accidental trauma.

Other features and advantages of the invention will be apparent from the following description of the embodiments thereof, and from the claims.

Throughout this specification the word comprise, or variations such as comprises or comprising, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Brief Description of the Drawings

Figs. 1 A-1G are photomicrographs showing the effect on bone formation 8 weeks following treatment. Fig. 1A is a photomicrograph showing the effect of surgery alone on bone formation. Fig. IB is a photomicrograph showing the effect of β-TCP alone on bone formation. Fig. 1C is a photomicrograph showing the effect of β-TCP + 0.3 mg/mL PDGF on bone formation. Fig. ID is a photomicrograph showing the effect of β-TCP + 1.0 mg/mL PDGF on bone formation. Fig. IE is a photomicrograph showing the effect of demineralized freeze dried bone allograft (DFDBA) alone on bone formation. Fig. IF is a photomicrograph showing the effect of demineralized freeze dried bone allograft (DFDBA) + 0.3 mg/mL PDGF on bone formation. Fig. 1G is a photomicrograph showing the effect of demineralized freeze dried bone allograft (DFDBA) + 1.0 mg/mL on bone formation.

Figs. 2A-2C are photomicrographs showing the effect on bone formation 16 weeks following treatment. Fig. 2 A is a photomicrograph showing the effect of β-TCP alone on bone formation. Fig. 2B is a photomicrograph showing the effect of β2006/044334

PCT/US2005/036447

TCP + 0.3 mg/mL PDGF on bone formation. Fig. 2C is a photomicrograph showing the effect of /3-TCP + 1.0 mg/mL PDGF on bone formation.

Detailed Description

We now describe several embodiments of the invention. Two examples demonstrating the use of PDGF as a bone and periodontum healing agent are presented below.

EXAMPLES

Example I: Preparation of PDGF

Osseous wounds, e.g., following periodontal disease or trauma, are treated and periodontium, including bone, cementum, and connective tissue, are regenerated, according to the invention by combining partially purified or purified PDGF with any of the pharmaceutically acceptable carrier substances described above. Purified PDGF can be obtained from a recombinant source or from human platelets. Commercially available recombinant PDGF can be obtained from R&amp;D Systems fric. (Minneapolis, MN), BD Biosciences (San Jose, CA), and Chemicon, International (Temecula, CA). Partially purified and purified PDGF can also be prepared as follows:

Five hundred to 1000 units of washed human platelet pellets are suspended in 1M NaCl (2 ml per platelet unit) and heated at 100°C for 15 minutes. The supernatant is then separated by centrifugation and the precipitate extracted twice with the lm

NaCl.

The extracts are combined and dialyzed against 0.08M NaCl / 0.01M sodium phosphate buffer (pH 7.4) and mixed overnight at 4°C with CM-Sephadex C-50

2006/044334

PCT/LS2005/036447 equilibrated with the buffer. The mixture is then poured into a column (5 x 100 cm), washed extensively with 0.08M NaCl / 0.01M sodium phosphate buffer (pH 7.4), and eluted with 1M NaCl while 10 ml fractions are collected.

Active fractions are pooled and dialyzed against 0.3M NaCl / 0.01M sodium phosphate buffer (pH 7.4), centrifuged, and passed at 4°C through a 2.5 x 25 cm column of blue sepliarose (Pharmacia) equilibrated with 0.3M NaCl / 0.01M sodium phosphate buffer (pH 7.4). The column is then washed with the buffer and partially purified PDGF eluted with a 1:1 solution of 1M NaCl and ethylene glycol.

The partially purified PDGF fractions are diluted (1:1) with 1M NaCl, dialyzed against 1M acetic acid, and lyophilized. The lyophilized samples are dissolved in 0.8M NaCl / 0.01M sodium phosphate buffer (pH 7.4) and passed through a 1.2 x 40 cm column of CM-Sephadex C-50 equilibrated with the buffer.

PDGF is then eluted with a NaCl gradient (0.08 to 1M).

The active fractions are combined, dialyzed against 1M acetic acid, lyophilized, and dissolved in a small volume of 1M acetic acid. 0.5 ml portions are applied to a 1.2 x 100 cm column of Biogel P-150 (100 to 200 mesh) equilibrated with 1M acetic acid. The PDGF is then eluted with 1M acetic acid while 2 mL fractions are collected.

Each active fraction containing 100 to 200 mg of protein is lyophilized, dissolved in 100 mL of 0.4% trifluoroacetic acid, and subjected to reverse phase high performance liquid chromatography on a phenyl Bondapak column (Waters). Elution with a linear acetonitrile gradient (0 to 60%) yields pure PDGF.

2006/044334

PCT/LS2005/036447

PDGF Made By Recombinant DNA Technology Can Be Prepared As Follows:

Platelet-derived growth factor (PDGF) derived from human platelets contains two polypeptide sequences (PDGF-B and PDGF-A polypeptides; Antoniades, H.N. and Hunkapiller, M., Science 220:963-965, 1983). PDGF-B is encoded by a gene localized on chromosome 7 (Betsholtz, C. et al., Nature 320:695-699), and PDGF-A is encoded by the sis oncogene (Doolittle, R. et al., Science 221:275-277, 1983) localized on chromosome 22 (Dalla-Favera, R., Science 218:686-688, 1982). The sis gene encodes the transforming protein of the Simian Sarcoma Virus (SSV) which is closely related to PDGF-2 polypeptide. The human cellular c-sis also encodes the PDGF-A chain (Rao, C. D. et al., Proc. Natl. Acad. Sci. USA 83:2392-2396, 1986). Because the two polypeptide chains of PDGF are coded by two different genes localized in separate chromosomes, the possibility exists that human PDGF consists of a disulfide-linked heterodimer of PDGF-B and PDGF-A, or a mixture of the two homodimers (PDGF-BB homodimer and PDGF-AA homodimer), or a mixture of the heterodimer and the two homodimers.

Mammalian cells in culture infected with the Simian Sarcoma Virus, which contains the gene encoding the PDGF-A chain, were shown to synthesize the PDGFA polypeptide and to process it into a disulfide-linked homodimer (Robbins et al., Nature 305:605-608,1983). In addition, the PDGF-A homodimer reacts with antisera raised against human PDGF. Furthermore, the functional properties of the secreted PDGF-A homodimer are similar to those of platelet-derived PDGF in that it stimulates DNA synthesis in cultured fibroblasts, it induces phosphorylation at the tyrosine residue of a 185 kD cell membrane protein, and it is capable of competing with human (¹²⁵I)-PDGF for binding to specific cell surface PDGF receptors (Owen, A. et al., Science 225:54-56, 1984). Similar properties were shown for the sis/PDGF31

WO 2006/044334

PCT/US2005/036447

A gene product derived from cultured normal human cells (for example, human arterial endothelial cells), or from human malignant cells expressing the sis/PDGF-2 gene (Antoniades, H. et al., Cancer Cells 3:145-151, 1985).

The recombinant PDGF-B homodimer is obtained by the introduction of 5 cDNA clones of c-sis/PDGF-B gene into mouse cells using an expression vector. The c-sis/PDGF-B clone used for the expression was obtained from normal human cultured endothelial cells (Collins, T., et al., Nature 216:748-750, 1985).

Use of PDGF

PDGF alone or in combination with other growth factors is useful for promoting bone healing, bone growth and regeneration or healing of the supporting structures of teeth injured by trauma or disease. It is also useful for promoting healing of a site of extraction of a tooth, for mandibular ridge augmentation, or at tooth implant sites. Bone healing would also be enhanced at sites of bone fracture or in infected areas, e.g., osteomyelitis, or at tumor sites. PDGF is also useful for promoting growth and healing of a ligament, e.g., the periodontal ligament, and of cementum.

In use, the PDGF or other growth or differentiation factor is applied directly to the area needing healing or regeneration. Generally, it is applied in a resorbable or non-resorbable carrier as a liquid or solid, and the site then covered with a bandage or nearby tissue. An amount sufficient to promote bone growth is generally between 500 ng and 5 mg for a 1 cm² area, but the upper limit is really 1 mg for a 1 cm² area, with a preferred amount of PDGF applied being 0.3 mg/mL.

2006/044334

PCT/US2005/036447

Example II: Periodontal Regeneration With rhPDGF-BB Treated Osteoconductive Scaffolds

The effectiveness of PDGF in promoting periodontium and bone growth is demonstrated by the following study.

In Vivo Dog Study

The beagle dog is the most widely used animal model for testing putative periodontal regeneration materials and procedures (Wikesjo et al., J. Clin.

Periodontol. 15:73-78, 1988; Wikesjo et al., J. Clin. Periodontol. 16:116-119, 1999;

Cho et al., J. Periodontol. 66:522-530, 1995; Giannobile et al., J. Periodontol. 69:129-137, 1998; and Clergeau et al., J. Periodontol. 67:140-149, 1996). Plaque and calculus accumulation can induce gingival inflammation that may lead to marginal bone loss and the etiology of periodontitis in dogs and humans can be compared. In naturally occurring disease, however, there is a lack of uniformity between defects. Additionally, as more attention has been given to oral health in canine breeder colonies, it has become impractical to obtain animals with natural periodontal disease. Therefore, the surgically-induced horizontal Class ΙΠ furcation model has become one of the most commonly used models to investigate periodontal healing and regeneration.

Beagle dogs with horizontal Class III furcation defects were treated using PDGF compositions of the invention. Fifteen adult beagle dogs contributed 60 treated defects. Forty-two defects were biopsied two months after treatment and fifteen defects were biopsied four months after treatment

2006/044334

PCT/US2005/036447

Defect Preparation

The “critical-size” periodontal defect model as described by numerous investigators was utilized (see, e.g., Wikesjo, 1988 and 1999, supra; Giannobile, supra, Cho, supra, and Park et al., J. Periodontol. 66:462-477, 1995). Both mandibular quadrants in 16 male beagle dogs (2-3 years old) without general and oral health problems were used. One month prior to dosing, the animals were sedated with a subcutaneous injection of atropine (0.02 mg/kg) and acepromazine (0.2 mg/kg) approximately 30 minutes prior to being anesthetized with an IV injection of pentobarbital sodium (25 mg/kg). Following local infiltration of the surgical area with Lidocaine HCI plus epinephrine 1:100,000, full thickness mucoperiosteal flaps were reflected and the first and third premolars (Pl and P3) were extracted. Additionally, the mesial portion of the crown of the 1st molar was resected.

Alveolar bone was then removed around the entire circumference of P2 and

P4, including the furcation areas using chisels and water-cooled carbide and diamond burs. Horizontal bone defects were created such that there was a distance of 5 mm from the fornix of the furcation to the crest of the bone. The defects were approximately 1 cm wide, depending on the width of the tooth. The roots of all experimental teeth were planed with curettes and ultrasonic instruments and instrumented with a tapered diamond bur to remove cementum. After the standardized bone defects were created the gingival flaps were sutured to achieve primary closure. The animals were fed a soft diet and received daily chlorhexidine rinses for the duration of the study.

WO 2006/044334

PCT/US2005/036447

Application of Graft Material

The periodontal defects of P2 and P4 in each mandibular quadrant of the 15 animals were randomized prior to treatment using sealed envelopes. About four weeks after defect preparation, animals were re-anesthetized as described above and full thickness flaps were reflected in both mandibular quadrants. A notch was placed in the tooth root surfaces at the residual osseous crest using a 1/2 round bur to serve as a future histologic reference point. The sites were irrigated with sterile saline and the roots were treated with citric acid as described previously for the purpose of decontamination and removal of the smear layer (See, e.g., Cho, supra, and Park, supra). During this period an amount of/3-TCP or DFDBA sufficient to fill the periodontal defect was saturated with a solution of rhPDGF-BB solution (0.3 or 1.0 mg/ml) and the rhPDGF-BB/graft mixture was allowed to sit on the sterile surgical stand for about ten minutes. The rhPDGF-BB saturated graft was then packed into the defect with gentle pressure to the ideal level of osseous regeneration.

After implantation of the graft material, the mucoperiosteal flaps were sutured approximately level to the cementoenamel junction (CEJ) using interproximal, interrupted 4.0 expanded polytetrafluoroethylene (ePTFE) sutures. Following suturing of the flaps chlorhexidine gluconate gel was gently placed around the teeth and gingivae.

WO 2006/044334

PCT/LS2005/036447

Treatment and Control Groups

Defects received either:

1. 0-TCP

2. β-TCP plus rhPDGF-BB (0.3 mg/ml rhPDGF-BB)

3. β-TCP plus rhPDGF-BB (1.0 mg/ml rhPDGF-BB)

4. Dog DFDBA

5. Dog DFDBA plus rhPDGF-BB (0.3 mg/ml rhPDGF-BB)

6. Dog DFDBA plus rhPDGF-BB (1.0 mg/ml rhPDGF-BB)

7. Sham surgery (treated by open flap debridement only, no graft)

Six defects per treatment group were biopsied at two months (42 total sites).

In addition, five defects in treatment groups 1,2, and 3 were biopsied at four months (15 total sites).

Table 2. Experimental design

<td> Group No.</td><td> NO. OF Test Sites</td><td> Treatment</td><td> Time Points</td>

<td> 1</td><td> 11</td><td> β-TCP alone</td><td> 8 &amp; 16 weeks n=6 for 8 wk n=5 for 16wk</td>

<td> 2</td><td> 11</td><td> β-TCP + 0.3 mg/ml rhPDGF-BB</td><td> 8 &amp; 16 weeks n=6 for 8 wk n=5 for 16 wk</td>

<td> 3</td><td> 11</td><td> β-TCP + 1.0 mg/ml rhPDGF-BB</td><td> 8 &amp; 16 weeks n=6 for 8 wk n=5 for 16 wk</td>

<td> 4</td><td> 6</td><td> DFDBA alone</td><td> 8 weeks</td>

<td> 5</td><td> 6</td><td> DFDBA + 0.3 mg/ml rhPDGF-BB</td><td> 8 weeks</td>

<td> 6</td><td> 6</td><td> DFDBA + 1.0 mg/ml rhPDGF-BB</td><td> 8 weeks</td>

<td> 7</td><td> 6</td><td> Surgery, no graft</td><td> 8 weeks</td>

WO 2006/044334

PCT/LS2005/036447

Accordingly, at 8 weeks there are 7 groups divided among 42 sites in 11 dogs. At 16 weeks, there are 3 groups divided among 15 sites in 4 dogs (one dog received two treatment surgeries staggered eight weeks apart and thus contributed two sites to each the 8 and 16 week time points).

Post-surgical Treatment

The surgical sites were protected by feeding the dogs a soft diet during the first 4 weeks post-operative. To insure optimal healing, systemic antibiotic treatment with penicillin G benzathine was provided for the first two weeks and plaque control was maintained by daily irrigation with 2 % chlorhexidine gluconate throughout the experiment. Sutures were removed after 3 weeks.

Data Collection

Rationale for Data Collection Points

The eight week time point was chosen because this is the most common time point reported for this model in the literature and therefore there are substantial historical data. For example, Wikesjo et al., supra, and Giannobile et al., supra, also chose 8 weeks to assess the regenerative effects of BMP-2 and OP-1, respectively, in the same model. Additionally, Park et al., supra, evaluated the effect or rhPDGF-BB applied directly to the conditioned root surface with and without GTR membranes in the beagle dog model at 8 weeks. These studies, strongly suggest that the 8 week period should be optimal for illustrating potential significant effects among the various treatment modalities.

WO 2006/044334

PCT/US2005/036447

The sixteen week time point was chosen to assess long-term effects of growth factor treatment. Previous studies (Park et al., supra) suggest that by this time there is substantial spontaneous healing of the osseous defects. Nevertheless, it is possible to assess whether rhPDGF-BB treatment leads to any unusual or abnormal tissue response, such as altered bone remodeling, tumorgenesis or root resorption.

Biopsies and Treatment Assessments

At the time of biopsy, the animals were perfused with 4% paraformaldehyde and sacrificed. The mandibles were then removed and placed in fixative. Periapical radiographs were taken and the treated sites were cut into individual blocks using a diamond saw. The coded (blinded) blocks were wrapped in gauze, immersed in a solution of 4% formaldehyde, processed, and analyzed.

During processing the biopsies were dehydrated in ethanol and infiltrated and embedded in methylmethacrylate. Undecalcified sections of approximately 300 /zm in thickness were obtained using a low speed diamond saw with coolant. The sections were glued onto opalescent acrylic glass, ground to a final thickness of approximately 80 /zm, and stained with toludine blue and basic fuchsin. Step serial sections were obtained in a mesiodistal plane.

Histomorphometric analyses were performed on the masked slides. The following parameters were assessed:

1. Length of Complete New Attachment Apparatus (CNAA): Periodontal regeneration measured as the distance between the coronal level of the old bone and the coronal level of the new bone, including only that new bone adjacent to new

WO 2006/044334

PCT/US2005/036447 cementum with functionally oriented periodontal ligament between the new bone and new cementum.

2. New Bone Fill (NB): Measured as the cross-sectional area of new bone formed within the furcation.

3. Connective Tissue fill (CT): Measured as the area within the furcation occupied by gingival connective tissue.

4. Void (VO): The area of recession where there is an absence of tissue.

Results

A. Clinical observations

Clinically, all sites healed well. There was an impression that the sites treated ?· with rhPDGF-BB healed more quickly, as indicated by the presence of firm, pink gingivae within one week post-operatively. There were no adverse events experienced in any treatment group as assessed by visual inspection of the treated 15 sites. There appeared to be increased gingival recession in groups that received βTCP or DFDBA alone.

B. Radiographic observations

Radiographically, there was evidence of increased bone formation at two 20 months as judged by increased radiopacity in Groups 2, 3 (β-TCP + rhPDGF-BB 0.3 and 1.0 mg/ml, respectively) and 6 (DFDBA + rhPDGF-BB 1.0 mg/ml) compared to the other groups (Figures 1A-G). At four months, there was evidence of increased bone formation in all groups compared to the two month time point. There was no radiographic evidence of any abnormal bone remodeling, root resorption, or ankylosis in any group.

WO 2006/044334

PCT/US2005/036447

Table 3. Radiographic results. Rank order.

<td> Qualitative assessment OF BONE FILL AT 8 WKS*</td><td> Treatment</td>

<td> 6</td><td> β-TCP alone</td>

<td> 1</td><td> β-TCP + 0.3 mg/ml rhPDGF</td>

<td> 2</td><td> β-TCP + 1.0 mg/ml rhPDGF</td>

<td> 7</td><td> DFDBA alone</td>

<td> 5</td><td> DFDBA + 0.3 mg/ml rhPDGF</td>

<td> 3</td><td> DFDBA + 1.0 mg/ml rhPDGF</td>

<td> 4</td><td> Surgery, no graft</td>

* 1= most fill; 7= least fill

C. Histomorphometric analyses:

Histomorphometric assessment of the length of new cementum, new bone, and new periodontal ligament (CNAA) as well as new bone fill, connective tissue fill, and void space were evaluated and are expressed as percentages. In the case of CNAA, values for each test group represent the CNAA measurements (length in mm)/ total available CNAA length (in mm) x 100%. Bone fill, connective tissue fill and void space were evaluated and are expressed as percentages of the total furcation defect area.

One-way analysis of variance (ANOVA) was used to test for overall differences among treatment groups, and pairwise comparisons were made using the student’s t-test. Significant differences between groups were found upon analyses of the coded slides. Table 4 shows the results at two months.

WO 2006/044334

PCT/US2005/036447

Table 4. Two month histometric analyses

<td> Group No.</td><td> Treatment</td><td> % CNAA PERIODONTAL REGENERATION</td><td> % BONE FILL</td><td> % CONNECTIVE tissue Fill</td><td> % Void</td>

<td> 1</td><td> β-TCP alone</td><td> 37.0 ±22.8</td><td> 28.0 ±29.5</td><td> 36.0 ±21.5</td><td> 12.0 ±17.9</td>

<td> 2</td><td> β-TCP + 0.3 mg/ml rhPDGF</td><td> 59.0 ± 19.1 *4</td><td> 84.0 ± 35.8 t, t</td><td> 0.0 ±0.0</td><td> 8.0 ± 17.9</td>

<td> 3</td><td> β-TCP + 1.0 mg/ml rhPDGF</td><td> 46.0 ± 12.3 *</td><td> 74.2 ±31.7 t</td><td> 0.0 ± 0.0</td><td> 0.0 ±0.0</td>

<td> 4</td><td> DFDBA alone</td><td> 13.4 ± 12.0</td><td> 6.0 ±8.9</td><td> 26.0 ± 19.5</td><td> 30.0 ±27.4</td>

<td> 5</td><td> DFDBA + 0.3 mg/ml rhPDGF</td><td> 21.5 ± 13.3</td><td> 20.0 ± 18.7</td><td> 36.0 ± 13.4</td><td> 18.0 ± 21.7</td>

<td> 6</td><td> DFDBA + 1.0 mg/ml rhPDGF</td><td> 29.9 ± 12.4</td><td> 46.0 ±23.0</td><td> 26.0 ±5.48</td><td> 8.0 ± 13.04</td>

<td> 7</td><td> Sham Surgery, no graft</td><td> 27.4 ± 15.0</td><td> 34.0 ± 27.0</td><td> 48.0 ±35.64</td><td> 10.0 ±22.4</td>

* Groups 2 and 3 significantly greater (p&lt;0.05) than Groups 4 and 7. **Group 1 significantly greater (p&lt;0.05) than Group 4.

f Group 2 significantly greater (p&lt;0.05) than Group 5.

| Groups 2 and 3 significantly greater than Groups 1, 4 and 7.

Group 6 significantly greater than Group 4.

The mean percent periodontal regeneration (CNAA) in the surgery without grafts and surgery plus /3-TCP alone groups were 27% and 37%, respectively. In contrast, /3-TCP groups containing rhPDGF-BB exhibited significantly greater periodontal regeneration (p&lt;0.05) than surgery without grafts or DFDBA alone (59% and 46% respectively for the 0.3 and 1.0 mg/ml concentrations versus 27% for surgery alone and 13% for DFDBA alone). Finally, the /3-TCP group containing 0.3 mg/ml rhPDGF-BB demonstrated significantly greater periodontal regeneration (p&lt;0.05) than the same concentration of rhPDGF-BB combined with allograft (59% versus 21%).

Bone fill was significantly greater (p&lt;0.05) in the /3-TCP + 0.3 mg/ml rhPDGF-BB (84.0%) and the /3-TCP + 1.0 mg/ml rhPDGF-BB (74.2%) groups than in the /3-TCP alone (28.0%), surgery alone (34%) or DFDBA alone (6%) treatment

WO 2006/044334

PCT/US2005/036447 groups. There was also significantly greater bone fill (p&lt;0.05) for the /3-TCP + 0.3 mg/ml rhPDGF-BB group compared to the DFDBA + 0.3 mg/ml rhPDGF-BB group (84% and 20% respectively).

The group of analyses examining the 8-week data from the DFDBA groups 5 and the surgery alone group (Groups 4, 5, 6, and 7) demonstrated no statistically significant differences between the DFDBA groups and surgery alone for periodontal regeneration (CNAA). There was a trend toward greater regeneration for those sites treated with the 1.0 mg/ml rhPDGF-BB enhanced DFDBA versus DFDBA alone. There was significantly greater bone fill (p&lt;0.05) for sites treated with DFDBA + 1.0 mg/ml rhPDGF-BB than DFDBA alone (46 and 6% respectively). There was a trend toward greater bone fill for sites treated with DFDBA containing 0.3 mg/ml rhPDGFBB compared to DFDBA alone or surgery alone. However, sites treated with DFDBA alone demonstrated less bone fill into the defect than surgery alone (6 and 34%, respectively), with most of the defect being devoid of any fill or fill consisting of gingival (soft) connective tissue.

At four months following treatment, there remained significant differences in periodontal regeneration. /3-TCP alone, as a result of extensive ankylosis, resulted in 36% regeneration, while the sites treated with /3-TCP containing rhPDGF-BB had a mean regeneration of 58% and 49% in the 0.3 and 1.0 mg/ml rhPDGF-BB concentrations. Substantial bone fill was present in all three treatment groups. /3-TCP alone resulted in 70% bone fill, /3-TCP plus 0.3 mg/ml rhPDGF yielded 100% fill while the 1.0 mg/ml rhPDGF group had 75% fill.

WO 2006/044334

PCT/US2005/036447

D. Histologic Evaluation

Histologic evaluation was performed for all biopsies except one, in which evaluation was not possible due to difficulties encountered during processing.

Representative photomicrographs are shown in Figures 1A-G and 2A-C.

Figure 1A shows results from a site treated with surgery alone (no grafts). This specimen demonstrates limited periodontal regeneration (new bone (NB), new cementum (NC), and periodontal ligament (PDL)) as evidenced in the area of the notches and extending only a short distance coronally. The area of the furcation is occupied primarily by dense soft connective tissue (CT) with minimal new bone (NB) formation.

For sites treated with /3-TCP alone (Figure IB) there is periodontal regeneration, similar to that observed for the surgery alone specimen, that extends from the base of the notches for a short distance coronally. As was seen in the surgery alone specimens, there was very little new bone formation with the greatest area of the furcation being occupied by soft connective tissue.

In contrast, Figure 1C illustrates results obtained for sites treated with /3-TCP + 0.3 mg/ml rhPDGF-BB. Significant periodontal regeneration is shown with new bone, new cementum, and periodontal ligament extending along the entire surface of the furcation. Additionally, the area of the furcation is filled with new bone that extends the entire height of the furcation to the fornix.

Representative results for sites treated with /3-TCP +1.0 mg/ml rhPDGF-BB are shown in Figure ID. While there is significant periodontal regeneration in the furcation, it does not extend along the entire surface of the furcation. There is new

WO 2006/044334

PCT/LS2005/036447 bone formation present along with soft connective tissue that is observed at the coronal portion of the defect along with a small space which is void of any tissue (VO) at the fornix of the furcation.

Figures 2A, 2B, and 2C illustrate results obtained for the allograft treatment 5 groups. Representative results for the DFDBA alone group (Figure 2A) shows very poor periodontal regeneration that is limited to the area of the notches extending only slightly in a coronal direction. New bone formation is limited and consists of small amounts of bone formation along the surface of residual DFDBA graft material (dark red staining along lighter pink islands). Additionally, the new bone is surrounded by extensive soft connective tissue that extends coronally to fill a significant area within the furcation. Finally, a large void space extends from the coronal extent of the soft connective tissue to the fornix of the furcation.

Histologic results for the DFDBA + 0.3 and 1.0 mg/ml rhPDGF-BB are shown in Figures 2B and 2C, respectively. Both groups demonstrate greater periodontal regeneration compared to DFDBA alone with a complete new attachment apparatus (new bone, new cementum, and periodontal ligament) extending from the base of the notches in the roots for a short distance coronally (arrows). They also had greater bone fill within the area of the furcation, although there was significant fill of the furcation with soft connective tissue.

WO 2006/044334

PCT/US2005/036447

Conclusions

Based on the results of the study, treatment of a periodontal defect using rhPDGF-BB at either 0.3 mg/mL or 1.0 mg/mL in combination with a suitable carrier material (e.g., /3-TCP) results in greater periodontal regeneration than the current products or procedures, such as grafts with /3-TCP or bone allograft alone, or periodontal surgery without grafts.

Treatment with the 0.3 mg/mL and 1.0 mg/mL concentration of rhPDGF resulted in periodontal regeneration. The 0.3 mg/ml concentration of rhPDGF demonstrated greater periodontal regeneration and percent bone fill as compared to the 1.0 mg/ml concentration of rhPDGF when mixed with /3-TCP.

β-TCP was more effective than allograft when mixed with rhPDGF-BB at any concentration. The new bone matured (remodeled) normally over time (0, 8, and 16 weeks) in all groups. There was no increase in ankylosis or root resorption in the rhPDGF groups. In fact, sites receiving rhPDGF-BB tended to have less ankylosis than control sites. This finding may result from the fact that rhPDGF-BB is mitogenic and chemotactic for periodontal ligament cells.

MATERIALS AND METHODS

Materials Utilized: Test and Control Articles

The /3-TCP utilized had a particle-size (0.25 mm - 1.0 mm) that was optimized for periodontal use. Based on studies using a canine model, administered β-TCP is ~80% resorbed within three months and is replaced by autologous bone during the healing process.

WO 2006/044334

PCT/LS2005/036447

The DFDBA was supplied by Musculoskeletal Transplant Foundation (MTF).

The material was dog allograft, made by from the bones of a dog that was killed following completion of another study that tested a surgical procedure that was deemed to have no effect on skeletal tissues.

Recombinant hPDGF-BB was supplied by BioMimetic Pharmaceuticals and was manufactured by Chiron, Inc, the only supplier of FDA-approved rhPDGF-BB for human use. This rhPDGF-BB was approved by the FDA as a wound healing product under the trade name of Regranex®.

One ml syringes containing 0.5 ml of sterile rhPDGF-BB at two separate concentrations prepared in conformance with FDA standards for human materials and according to current applicable Good Manufacturing Processes (cGMP).

Concentrations tested included 0.3 mg/ml and 1.0 mg/ml.

/3-TCP was provided in vials containing 0.5 cc of sterile particles.

DFDBA was provided in 2.0 ml syringes containing 1.0 cc of sterile, demineralized freeze-dried dog bone allograft.

2.

Material Preparation

At the time of the surgical procedure, the final implanted grafts were prepared by mixing the rhPDGF-BB solution with the matrix materials. Briefly, an amount of

TCP or allograft sufficient to completely fill the osseous defect was placed into a sterile dish. The rhPDGF-BB solution sufficient to completely saturate the matrix was then added, the materials were mixed and allowed to sit on the surgical tray for about 10 minutes at room temperature prior to being placed in the osseous defect.

WO 2006/044334

PCT/LS2005/036447

A 10 minute incubation time with the /3-TCP material is sufficient to obtain maximum adsorption of the growth factor (see Appendix A). This is also an appropriate amount of time for surgeons in a clinical setting to have prior to placement of the product into the periodontal defect. Similarly, in a commercial market, the rhPDGF-BB and the matrix material can be supplied in separate containers in a kit and that the materials can be mixed directly before placement. This kit concept would greatly simplify product shelf life/stability considerations.

Example III: Use of PDGF For The Treatment Of Periodontal Bone Defects in 10 Humans

Recombinant human PDGF-BB (rhPDGF-BB) was tested for its effect on the regeneration of periodontal bone in human subjects. Two test groups were administered rhPDGF-BB at either 0.3 mg/mL (Group I) or 1.0 mg/mL (Group II).

rhPDGF-BB was prepared in sodium acetate buffer and administered in a vehicle of beta-tricalcium phosphate (/3-TCP). The control group, Group III, was administered /3-TCP in sodium acetate buffer only.

The objective of clinical study was to evaluate the safety and effectiveness of graft material comprising /3-TCP and rhPDGF-BB at either 0.3 mg/mL or 1.0 mg/mL in the management of one (1) to three (3) wall intra-osseous periodontal defects and to assess its regenerative capability in bone and soft tissue.

Study Design and Duration of Treatment

The study was a double-blind, controlled, prospective, randomized, parallel designed, multi-center clinical trial in subjects who required surgical intervention to treat a bone defect adjacent to the natural dentition. The subjects were randomized in

WO 2006/044334

PCT/LS2005/036447 equal proportions to result in three (3) treatment groups of approximately 60 subjects each (180 total). The duration of the study was six (6) months following implantation of the study device. The study enrolled 180 subjects.

Diagnosis and Main Entry Criteria

Male and female subjects, 25-75 years of age, with advanced periodontal disease in at least one site requiring surgical treatment to correct a bone defect were admitted to the study. Other inclusion criteria included: 1) a probing pocket depth measuring 7 mm or greater at the baseline visit; 2) after surgical debridement, 4 mm or greater vertical bone defect (BD) with at least 1 bony wall; 3) sufficient keratinized tissue to allow complete tissue coverage of the defect; and, 4) radiographic base of defect at least 3 mm coronal to the apex of the tooth. Subjects who smoked up to 1 pack a day and who had teeth with Class I &amp; II furcation involvement were specifically allowed.

Dose and Mode of Administration

All treatment kits contained 0.25 g of /3-TCP (an active control) and either 0.5 mL sodium acetate buffer solution alone (Group IH), 0.3 mg/mL rhPDGF-BB (Group I), or 1.0 mg/mL rhPDGF-BB (Group II).

Following thorough debridement and root planing, the test solution was mixed with /3-TCP in a sterile container, such that the /3-TCP was fully saturated. Root surfaces were conditioned using either tetracycline, EDTA, or citric acid. The hydrated graft was then packed into the osseous defect and the tissue flaps were secured with interdental sutures to achieve complete coverage of the surgical site.

WO 2006/044334

PCT/LS2005/036447

Effectiveness Measurement

The primary effectiveness measurement included the change in clinical attachment level (CAL) between baseline and six months post-surgery (Group I vs. Group III). The secondary effectiveness measurements consisted of the following outcomes: 1) linear bone growth (LBG) and % bone fill (%BF) from baseline to six months post-surgery based on the radiographic assessments (Group I and Group II vs. Group III); 2) change in CAL between baseline and six months post-surgery (Group II vs. Group III); 3) probing pocket depth reduction (PDR) between baseline and six months post-surgery (Group I and Group II vs. Group III); 4) gingival recession (GR) between baseline and six months post-surgery (Group I and Group II vs. Group III);

5) wound healing (WH) of the surgical site during the first three weeks post-surgery (Group I and Group II vs. Group III); 6) area under the curve for the change in CAL between baseline and three (3) and six (6) months (Group I and Group II vs. Group III); 7) the 95% lower confidence bound (LCB) for %BF at six (6) months post15 surgery (Groups I, II, and ΠΙ vs. demineralized freeze-dried bone allograft (DFDBA) as published in the literature; Parashis et al., J. Periodontol. 69:751-758, 1998); 8) the 95% LCB for linear bone growth at six (6) months post-surgery (Groups I, II, and HI vs. demineralized freeze-dried bone allograft (DFDBA) as published in the literature;

Persson et al., J. Clin. Periodontol. 27:104-108, 2000); 9) the 95% LCB for the change in CAL between baseline and six (6) months (Groups I, IL and II vs. EMDOGAIN® PMA P930021, 1996); and 10) the 95% LCB for the change in CAL between baseline and six (6) months (Groups I, II and III vs. PEPGEN P-15™ - PMA P990033, 1999).

WO 2006/044334

PCT/LS2005/036447

Statistical Methods

Safety and effectiveness data were examined and summarized by descriptive statistics. Categorical measurements were displayed as counts and percents, and continuous variables were displayed as means, medians, standard deviations and ranges. Statistical comparisons between the test product treatment groups (Groups I and II) and the control (Group III) were made using Chi-Square and Fisher’s Exact tests for categorical variables and t-tests or Analysis of Variance Methods (ANOVA) for continuous variables. Comparisons between treatment groups for ordinal variables were made using Cochran-Mantel-Haenszel methods. A p&lt;0.05 (one sided) was considered to be statistically significant for CAL, LBG and %BF.

Safety data were assessed by the frequency and severity of adverse events as evaluated clinically and radiographically. There were no significant differences between the three treatment groups at baseline. There were also no statistically significant differences observed in the incidence of adverse events (AEs; all causes) among the three treatment groups. The safety analysis did not identify any increased risk to the subject due to implantation of the graft material.

Summary of Effectiveness Results

The results from the statistical analyses revealed both clinically and 20 statistically significant benefits for the two treatment groups (Groups I and II), compared to the active control of /3-TCP alone (Group III) and historical controls including DFDBA, EMDOGAIN®, and PEPGEN P-15™.

At three months post-surgery, a statistically significant CAL gain from baseline was observed in favor of Group I versus Group III (p = 0.041), indicating that there are significant early benefits of PDGF on the gain in CAL. At six months

WO 2006/044334

PCT/LS2005/036447 post-surgery, this trend continued to favor Group I over Group ΠΙ, although this difference was not statistically significant (p = 0.200). The area under the curve analysis (AUC) which represents the cumulative effect (i.e. speed) for CAL gain between baseline and six months approached statistical significance favoring Group I in comparison to Group III (p=0.054). Further, the 95% lower confidence bound (LCB) analyses for all treatment groups substantiated the effectiveness of Groups I and II compared to the CAL gains observed at six (6) months for EMDOGAIN® and PEPGENP-15™.

In addition to the observed clinical benefits of CAL, radiographic analyses 10 including Linear Bone Growth (LBG) and Percent Bone Fill (%BF), revealed statistically significant improvement in bone gain for Groups I and II vs. Group ΠΙ. %BF was defined as the percent of the original osseous defect filled with new bone as measured radiographically. LBG showed significant improvement in Group I (2.5mm) when compared to Group III (0.9mm, p&lt;0.001). LBG was also significant for Group II (1.5mm) when compared to Group III (p=0.021).

Percent Bone Fill (%BF) was significantly increased at six months postsurgical in Group I (56%) and Group II (34%) when compared to Group III (18%), for a p&lt;0.001 and p=0.019, respectively. The 95% lower bound of the confidence interval at six months post-surgery, for both linear bone growth and % bone fill, substantiated the effectiveness of Groups I and II compared to the published radiographic results for DFDBA, the most widely used material for periodontal grafting procedures.

At three months, there was significantly less Gingival Recession (GR) (p=0.041) for Group I compared to Group III consistent with the beneficial effect observed with CAL. No statistically significant differences were observed in PDR

WO 2006/044334

PCT/LS2005/036447 and GR at six months. Descriptive analysis of the number of sites exhibiting complete wound healing (WH) at three weeks revealed improvements in Group I (72%) vs. Group II (60%) and Group ΙΠ (55%), indicating a trend toward improved healing.

To assess the cumulative beneficial effect for clinical and radiographic outcomes, a composite effectiveness analysis was performed to determine the percent of patients with a successful outcome as defined by CAL > 2.7mm and LBG > 1.1mm at six (6) months. The CAL and LBG benchmarks of success were established by the mean levels achieved for these parameters by the implanted grafts, as identified in the “Effectiveness Measures” section above. The results showed that 61.7% of Group I patients and 37.9% of Group II patients met or exceeded the composite benchmark for success compared to 30.4% of Group III patients, resulting in a statistically significant benefit of Group I vs. Group III (p<0.001). %BF revealed similar benefits for Group I (70.0%) vs. Group III (44.6%) for p-value of 0.003.

In summary, Group I achieved statistically beneficial results for CAL and GR at three (3) months as well as LBG and %BF at six (6) months, compared to the βTCP alone active control group (Group III). The clinical significance of these results is further confirmed by comparison to historical controls. It is concluded that PDGFcontaining graft material was shown to achieve clinical and radiographic effectiveness by six months for the treatment of periodontal osseous defects.

WO 2006/044334

PCT/LS2005/036447

Table 5: Summary of PDGF Graft Effectiveness

<td> Endpoint</td><td> Group I</td><td> Group H</td><td> Group m</td>

<td> CAL Gain (mm): 3 months</td><td> 3.8 (p=0.04)</td><td> 3.4 (p=0.40)</td><td> 3.3</td>

<td> CAL: AUC Analysis (mm x wk)</td><td> 67.5 (p=0.05)</td><td> 61.8 (p=0.35)</td><td> 60.1</td>

<td> CAL (mm): 95% LCB 6 months (vs 2.7 mm for EMDOGAIN &amp; 1.1 mm for PEPGEN)</td><td> 3.3</td><td> 3.2</td><td> 3.1</td>

<td> GR (mm): 3 months</td><td> 0.5 (p=0.04)</td><td> 0.7 (p=0.46)</td><td> 0.9</td>

<td> LBG (mm): 6 months</td><td> 2.5 (p&lt;0.001)</td><td> 1.5 (p=0.02)</td><td> 0.9</td>

<td> %BF: 6 months</td><td> 56.0 (p&lt;0.001)</td><td> 33.9 (p=0.02)</td><td> 17.9</td>

<td> Composite CAL-LBG Analysis</td><td> 61.7% (p&lt;0.001)</td><td> 37.9% (p=0.20)</td><td> 30.4%</td>

<td> (% Success) CAL-%BF</td><td> 70.0% (p=0.003)</td><td> 55.2% (p=0.13)</td><td> 44.6%</td>

Graft material (i.e., /3-TCP) containing PDGF at 0.3 mg/mL and at 1.0 mg/mL was shown to be safe and effective in the restoration of alveolar bone and clinical attachment around teeth with moderate to advanced periodontitis in a large, randomized clinical trial involving 180 subjects studied for up to 6 months. These conclusions are based upon validated radiographic and clinical measurements as summarized below.

Consistent with the biocompatibility data of the PDGF-containing graft material, discussed above, and the historical safe use of each individual component (i.e., /3-TCP alone or PDGF alone), the study revealed no evidence of either local or systemic adverse effects. There were no adverse outcomes attributable to the graft material, which was found to be safe.

WO 2006/044334

PCT/LS2005/036447

Conclusion

Implantation of /3-TCP containing PDGF at either 0.3 mg/mL or 1.0 mg/mL was found to be an effective treatment for the restoration of soft tissue attachment level and bone as shown by significantly improved CAL at 3 months compared to the 5 active control. Our findings are also consistent with the AUC analysis that showed an improvement in CAL gain between baseline and six months. Implantation of /3-TCP containing PDGF at either 0.3 mg/mL or 1.0 mg/mL was also found to be an effective treatment based on significantly improved LBG and %BF compared to the active control. Significantly improved clinical outcomes as shown by the composite analysis of both soft and hard tissue measurements compared to the /3-TCP alone active control also demonstrate the effectiveness of the treatment protocol described above. Finally, the results of administering /3-TCP containing PDGF at either 0.3 mg/mL or 1.0 mg/mL were found to exceed established benchmarks of effectiveness both clinically and radiographically.

The results of this trial together with extensive and confirmatory data from in vitro, animal and human studies demonstrate that PDGF-containing graft material stimulates soft and hard tissue regeneration in periodontal defects, although the effects were more significant when PDGF in the range of 0.1 to 1.0 mg/mL (e.g., 0.1 mg/mL, 0.3 mg/mL, or 1.0 mg/mL) was administered in the graft material. Moreover, PDGF administered in the graft material in the amount of 0.3 mg/mL effectively regenerated soft tissue and bone.

Other embodiments are within the following claims.